Exploring half-sandwich Ru(II)-hydroxamate complexes as next-generation anticancer agents with unique molecular architecture and promising therapeutic potential.
Exploring the interaction between a binuclear ruthenium complex and glycyl-L-leucine dipeptide, revealing insights for next-generation anticancer drugs.